
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 11/21/2013

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction of
incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 21, 2013, J. Tyler Martin, M.D., informed Dynavax Technologies Corporation that he had decided to resign from the Board of Directors, effective at the end of the year.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

The following exhibit is furnished herewith:

EX-99.1 Press Release, dated November 27, 2013, titled "Dynavax Announces Resignation of J. Tyler Martin From Board of Directors".

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: November 27, 2013

By: /s/ Michael Ostrach

Michael Ostrach
Vice President

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Dynavax Announces Resignation of J. Tyler Martin From Board of Directors.

Dynavax Technologies

2929 Seventh Street, Suite 100

Berkeley, CA 94710

Contact:

Michael Ostrach
Vice President and Chief Business
Officer
510-665-7257
mostrach@dynavax.com

DYNAVAX ANNOUNCES RESIGNATION OF J. TYLER MARTIN FROM BOARD OF DIRECTORS

BERKELEY, CA -- 11/27/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that J. Tyler Martin, M.D. plans to resign from the Board of Directors, effective at the end of the year. Dr. Martin, a director of the Company since 2010, decided to resign to devote more time to his other professional responsibilities. Dr. Martin is Founder and Chief Executive Officer of Great Plains Biotechnology, a strategic advisory group for biotechnology companies and investors.

"We thank Tyler for his leadership, expertise and contributions to Dynavax, both as a colleague on the Board and as our former President and Chief Medical Officer," said Arnold Oronsky, Ph.D., Chairman of Dynavax.

Dr. Martin added, "I am proud to have worked with Dynavax's other Board members and its employees and collaborators. With a new CEO and a path forward established for HEPLISAV™ in the US, Dynavax is well on its way to becoming a successful company that will bring benefit to many people."

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases and cancer. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.